Global Transcatheter Heart Valve Market Size, Share, and COVID-19 Impact Analysis, By Technology (Balloon Expanded Transcatheter Valve and Self-Expanded Transcatheter Valve), By Application (Transcatheter Aortic Valve, Transcatheter Pulmonary Valve, and Transcatheter Mitral Valve), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033.

Global Transcatheter Heart Valve Market Insights Forecasts to 2033

• The Global Transcatheter Heart Valve Market Size was Valued at USD 4.67 Billion in 2023
• The Market Size is Growing at a CAGR of 15.67% from 2023 to 2033
• The Worldwide Transcatheter Heart Valve Market Size is Expected to Reach USD 20.03 Billion by 2033
• Asia Pacific is expected to grow the fastest during the forecast period.

The Global Transcatheter Heart Valve Market Size is anticipated to exceed USD 20.03 billion by 2033, growing at a CAGR of 15.67% from 2023 to 2033. The prevalence of aortic stenosis can decline as a result of growing knowledge of transcatheter heart valve devices, which would subsequently drive the growth of the transcatheter heart valve market.

Market Overview

Transcatheter heart valve treatments have changed the results for patients with valvular heart disease (VHD) who are not suitable candidates for surgery. Technological developments have made it possible to extend these therapies to patients with various types of VHD, younger or lower-risk patients, and they can eventually allow for the early treatment of VHD in patients with moderate illness or fewer symptoms. Patients with lower and higher risk are anticipated to have different risk-benefit ratios, and further research is required to assess the overall effectiveness of transcatheter technology in these populations. Continuous improvements in THV design, developments in imaging and delivery systems, and the rising demand for minimally invasive surgeries that provide quicker recovery times, fewer complications, and lower healthcare costs than open-heart surgery are the main factors driving the transcatheter heart valve market. The demand for transcatheter heart valve (THV) treatments is mostly driven by the rising incidence of heart valve disorders, especially in the elderly population.       

 Report Coverage

This research report categorizes the transcatheter heart valve market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the transcatheter heart valve market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the transcatheter heart valve market.

Driving Factors

Demand for transcatheter heart valve (THV) treatments, like TAVR, is being driven by the increasing prevalence of heart valve illnesses, especially in the elderly population. This is especially true for conditions like mitral regurgitation and aortic stenosis. Continuous improvements in valve design, materials, and delivery systems have led to a high level of innovation that drives the transcatheter heart valve market. A further factor in the growth and diversification of the THV market is the focus on venturing into novel therapeutic domains, such as tricuspid and mitral valve treatments. Growth in the transcatheter heart valve market is anticipated to be driven by the rising incidence of aortic stenosis.  

Restraining Factors

High procedure and device costs, low awareness in emerging economies, regulatory obstacles, competition from surgical valve replacements, patient selection criteria, technology constraints, and a lack of long-term clinical data are the main factors restricting the transcatheter heart valve in the market.

Market Segmentation

The transcatheter heart valve market share is classified int technology and application.  

• The self-expanded transcatheter valve segment is estimated to hold the largest market revenue share through the projected period.  

Based on the technology, the transcatheter heart valve market is classified into balloon expanded transcatheter valve and self-expanded transcatheter valve. Among these, the self-expanded transcatheter valve segment is estimated to hold the largest market revenue share through the projected period. The first- and second-generation transcatheter heart valves make up the majority of the self-expanded transcatheter valve category, which aids in driving the market.  

• The transcatheter aortic valve segment is anticipated to hold the largest market share through the forecast period.  

Based on the application, the transcatheter heart valve market is divided into transcatheter aortic valve, transcatheter pulmonary valve, and transcatheter mitral valve. Among these, the transcatheter aortic valve segment is anticipated to hold the largest market share through the forecast period. The growing healthcare costs, an increase in the number of chronic heart conditions, and an increase in cases of severe aortic stenosis are the main drivers of the market in the transcatheter aortic valve segment.    

Regional Segment Analysis of the Transcatheter Heart Valve Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the transcatheter heart valve market over the predicted timeframe.

North America is anticipated to hold the largest share of the transcatheter heart valve market over the predicted timeframe. Strong healthcare spending, high awareness, and sophisticated healthcare infrastructure are the main factors driving the transcatheter heart valve market in North America. Modern medical technology and a high demand for minimally invasive procedures are advantageous to the region. The United States leads the world in THV technology adoption, largely due to important industry participants, advantageous reimbursement regulations, and strong healthcare systems.   

Asia Pacific is expected to grow at the fastest CAGR growth of the transcatheter heart valve market during the forecast period. A growing number of patients with cardiovascular problems as a result of changing lifestyles, urbanization, and an aging population is propelling the Asia Pacific transcatheter heart valve market to notable expansion.     

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the transcatheter heart valve market along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Medtronic  
• Abbott
• Edwards Lifesciences
• Meril Life Sciences
• Symetis
• Bracco Group
• Direct Flow Medical
• Braile Biomedica
• ValveXchange, Inc
• JenaValve
• Boston Scientific Corporation
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In December 2024, Vapi-oriented unveiling of Meril Life Sciences' Myval Octapro Transcatheter Heart Valve (THV) at GISE 2024 (National Congress of the Italian Society of Interventional Cardiology) and PCR London Valves 2024 marked a significant milestone for the leading global MedTech company that specializes in cardiovascular and structural heart solutions.  

• In November 2024, the experimental balloon-expandable transcatheter aortic valve implantation (TAVI) technology was launched by Abbott for patients suffering from severe aortic stenosis. In addition to providing a less invasive treatment alternative for patients at high risk for open heart surgery, this innovative device aims to enable AI-assisted treatments. 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the transcatheter heart valve market based on the below-mentioned segments: 

Global Transcatheter Heart Valve Market, By Technology

• Balloon Expanded Transcatheter Valve
• Self-Expanded Transcatheter Valve

Global Transcatheter Heart Valve Market, By Application

• Transcatheter Aortic Valve
• Transcatheter Pulmonary Valve
• Transcatheter Mitral Valve

Global Transcatheter Heart Valve Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa